$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > CheckMate227

纳武利尤单抗|最新研究

CheckMate-227研究6年随访结果公布,O+Y双免一线治疗持续改善非小
晚期肺癌患者长期生存率提高250%!免疫联合疗法最长随访结果!

伊匹木单抗|作用机制

抗CTLA-4抗体(yervoy)全面协同抗PD-1抗体 (opdivo),增强免疫系统抗